Neurocognitive Risk From PCSK9 Inhibitors Hinted in Meta-Analysis Neurocognitive Risk From PCSK9 Inhibitors Hinted in Meta-Analysis

The drugs work and are as safe as demonstrated in the clinical trials, but clinicians should be aware of these possible side effects and be vigilant in their patients, researchers say.Heartwire from Medscape

Source: Medscape Neurology and Neurosurgery Headlines - January 27, 2017 Category: Neurology Tags: Cardiology News Source Type: news